A phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer.
EUDRA-CT number:2016-003472-52
Study sites:
- UZ Leuven, Leuven
- UZ Gent, Gent
- AZ Maria Middelares, Gent
- Cliniques Universitaires Saint-Luc, Woluwe Saint-Lambert
- CHC-Clinique Saint-Joseph, Liège
- GZA Sint-Augustinus, Wilrijk
- AZ Turnhout, Turnhout
- Ziekenhuis Oost-Limburg, Genk
